Burning Rock Biotech Competitors

Natera (NASDAQ:NTRA) and Burning Rock Biotech (NASDAQ:BNR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Natera and Burning Rock Biotech, as reported by MarketBeat.com.

Natera presently has a consensus target price of $114.70, indicating a potential upside of 27.09%. Burning Rock Biotech has a consensus target price of $32.30, indicating a potential upside of 23.57%. Given Natera's higher possible upside, equities analysts clearly believe Natera is more favorable than Burning Rock Biotech.

Valuation and Earnings

This table compares Natera and Burning Rock Biotech's gross revenue, earnings per share and valuation.

Burning Rock Biotech has lower revenue, but higher earnings than Natera.

Profitability

This table compares Natera and Burning Rock Biotech's net margins, return on equity and return on assets.

Institutional and Insider Ownership

94.9% of Natera shares are held by institutional investors. Comparatively, 15.8% of Burning Rock Biotech shares are held by institutional investors. 9.3% of Natera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Natera beats Burning Rock Biotech on 5 of the 9 factors compared between the two stocks.

Invitae (NYSE:NVTA) and Burning Rock Biotech (NASDAQ:BNR) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Profitability

This table compares Invitae and Burning Rock Biotech's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Invitae and Burning Rock Biotech, as provided by MarketBeat.

Invitae presently has a consensus price target of $46.1667, suggesting a potential upside of 65.00%. Burning Rock Biotech has a consensus price target of $32.30, suggesting a potential upside of 23.57%. Given Invitae's higher probable upside, equities research analysts plainly believe Invitae is more favorable than Burning Rock Biotech.

Institutional and Insider Ownership

78.6% of Invitae shares are owned by institutional investors. Comparatively, 15.8% of Burning Rock Biotech shares are owned by institutional investors. 2.9% of Invitae shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Invitae and Burning Rock Biotech's top-line revenue, earnings per share and valuation.

Burning Rock Biotech has lower revenue, but higher earnings than Invitae.

Summary

Invitae beats Burning Rock Biotech on 5 of the 9 factors compared between the two stocks.

CareDx (NASDAQ:CDNA) and Burning Rock Biotech (NASDAQ:BNR) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares CareDx and Burning Rock Biotech's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for CareDx and Burning Rock Biotech, as provided by MarketBeat.

CareDx presently has a consensus price target of $75.6667, suggesting a potential upside of 15.08%. Burning Rock Biotech has a consensus price target of $32.30, suggesting a potential upside of 23.57%. Given Burning Rock Biotech's higher possible upside, analysts plainly believe Burning Rock Biotech is more favorable than CareDx.

Insider and Institutional Ownership

15.8% of Burning Rock Biotech shares are held by institutional investors. 3.1% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares CareDx and Burning Rock Biotech's gross revenue, earnings per share and valuation.

Burning Rock Biotech has lower revenue, but higher earnings than CareDx.

Summary

Burning Rock Biotech beats CareDx on 5 of the 9 factors compared between the two stocks.

Veracyte (NASDAQ:VCYT) and Burning Rock Biotech (NASDAQ:BNR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Veracyte and Burning Rock Biotech's top-line revenue, earnings per share and valuation.

Burning Rock Biotech has lower revenue, but higher earnings than Veracyte.

Analyst Recommendations

This is a summary of current recommendations for Veracyte and Burning Rock Biotech, as provided by MarketBeat.

Veracyte presently has a consensus price target of $58.4286, indicating a potential upside of 46.47%. Burning Rock Biotech has a consensus price target of $32.30, indicating a potential upside of 23.57%. Given Veracyte's higher probable upside, equities research analysts clearly believe Veracyte is more favorable than Burning Rock Biotech.

Institutional and Insider Ownership

15.8% of Burning Rock Biotech shares are owned by institutional investors. 8.3% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Veracyte and Burning Rock Biotech's net margins, return on equity and return on assets.

Summary

Burning Rock Biotech beats Veracyte on 5 of the 9 factors compared between the two stocks.

Burning Rock Biotech (NASDAQ:BNR) and Fulgent Genetics (NASDAQ:FLGT) are both mid-cap business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Burning Rock Biotech and Fulgent Genetics, as provided by MarketBeat.

Burning Rock Biotech presently has a consensus price target of $32.30, indicating a potential upside of 23.57%. Fulgent Genetics has a consensus price target of $74.40, indicating a potential upside of 6.26%. Given Burning Rock Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Burning Rock Biotech is more favorable than Fulgent Genetics.

Valuation & Earnings

This table compares Burning Rock Biotech and Fulgent Genetics' revenue, earnings per share (EPS) and valuation.

Burning Rock Biotech has higher earnings, but lower revenue than Fulgent Genetics.

Profitability

This table compares Burning Rock Biotech and Fulgent Genetics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

15.8% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 33.4% of Fulgent Genetics shares are held by institutional investors. 45.0% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Fulgent Genetics beats Burning Rock Biotech on 6 of the 9 factors compared between the two stocks.

Genetron (NASDAQ:GTH) and Burning Rock Biotech (NASDAQ:BNR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Valuation and Earnings

This table compares Genetron and Burning Rock Biotech's gross revenue, earnings per share and valuation.

Burning Rock Biotech has lower revenue, but higher earnings than Genetron.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Genetron and Burning Rock Biotech, as reported by MarketBeat.com.

Genetron presently has a consensus target price of $19.50, indicating a potential upside of 7.68%. Burning Rock Biotech has a consensus target price of $32.30, indicating a potential upside of 23.57%. Given Burning Rock Biotech's higher possible upside, analysts plainly believe Burning Rock Biotech is more favorable than Genetron.

Profitability

This table compares Genetron and Burning Rock Biotech's net margins, return on equity and return on assets.

Institutional and Insider Ownership

19.6% of Genetron shares are owned by institutional investors. Comparatively, 15.8% of Burning Rock Biotech shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.